Authors:
Verstuyft, C
Morin, S
Robert, A
Loriot, MA
Beaune, P
Jaillon, P
Becquemont, L
Citation: C. Verstuyft et al., Early acenocoumarol overanticoagulation among cytochrome P4502C9 poor metabolizers, PHARMACOGEN, 11(8), 2001, pp. 735-737
Authors:
Loriot, MA
Rebuissou, S
Oscarson, M
Cenee, S
Miyamoto, M
Ariyoshi, N
Kamataki, T
Hemon, D
Beaune, P
Stucker, I
Citation: Ma. Loriot et al., Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population, PHARMACOGEN, 11(1), 2001, pp. 39-44
Authors:
Cabelguenne, A
Loriot, MA
Stucker, I
Blons, H
Koum-Besson, E
Brasnu, D
Beaune, P
Laccourreye, O
Laurent-Puig, P
De Waziers, I
Citation: A. Cabelguenne et al., Glutathione-associated enzymes in head and neck squamous cell carcinoma and response to cisplatin-based neoadjuvant chemotherapy, INT J CANC, 93(5), 2001, pp. 725-730
Authors:
Wolkenstein, P
Loriot, MA
Aractingi, S
Cabelguenne, A
Beaune, P
Chosidow, O
Citation: P. Wolkenstein et al., Prospective evaluation of detoxification pathways as markers of cutaneous adverse reactions to sulphonamides in AIDS, PHARMACOGEN, 10(9), 2000, pp. 821-828
Authors:
Ariyoshi, N
Takahashi, Y
Miyamoto, M
Umetsu, Y
Daigo, S
Tateishi, T
Kobayashi, S
Mizorogi, Y
Loriot, MA
Stucker, I
Beaune, P
Kinoshita, M
Kamataki, T
Citation: N. Ariyoshi et al., Structural characterization of a new variant of the CYP2A6 gene (CYP2A61B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C, PHARMACOGEN, 10(8), 2000, pp. 687-693
Authors:
Colin, JF
Cazals-Hatem, D
Loriot, MA
Martinot-Peignoux, M
Pham, BN
Auperin, A
Degott, C
Benhamou, JP
Erlinger, S
Valla, D
Marcellin, P
Citation: Jf. Colin et al., Influence of human immunodeficiency virus infection on chronic hepatitis Bin homosexual men, HEPATOLOGY, 29(4), 1999, pp. 1306-1310